Skip to content
Yog Pharma
GastrointestinalAminosalicylate

Mesalamine is an aminosalicylate indicated for mildly to moderately active ulcerative colitis and maintenance of remission. We supply it to US manufacturers of delayed-release tablets, extended-release capsules, rectal suspension and suppositories.

CAS89-57-6153.1 g/molC7H7NO3
2D structure of Mesalamine.

Data from PubChem (CID 4075) and FDA’s substance registry

CAS number

89-57-6

Molecular formula

C7H7NO3

Molecular weight

153.1g/mol

FDA UNII

IUPAC name

5-amino-2-hydroxybenzoic acid

InChIKey

KBOPZPXVLCULAV-UHFFFAOYSA-N

Appearance
Light tan to pink, needle-shaped crystals.
Solubility
Slightly soluble in water. Soluble in dilute hydrochloric acid and in dilute alkali hydroxides.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Darkens as it oxidizes, so color and packaging are worth specifying. Doses are high, which makes bulk and tapped density matter for tablets and capsules.

On the US market

Reference product
PentasaNDA 020049
Approved ANDAs
32 with a marketed product
Approved forms and strengths
  • Extended-release capsule 250 mg, 375 mg, 500 mg
  • Delayed-release tablet 800 mg, 1.2 g
  • Suppository 1 g
  • Rectal enema 4 g/60 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com